Science News : ACC 2014 : Monday

Updated:Apr 1,2014
ACC14 Science News Masthead
ACC14 | March 29-13, 2014 | Washington, D.C.

Monday, March 31
Mariell Jessup, MD, FAHA, president of the American Heart Association, and Elliott Antman, MD, FAHA, president-electClyde Yancy, MD, past-president of the American Heart Association, discusses the results of the MSC-HF trial
Clyde Yancy, MD, past-president of the American Heart Association, discusses the results of MADIT-CRT (see study)Bob Bonow, MD, past-president of the American Heart Association discusses the results of the CHOICE trial (see study)

Session: 404 Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials
image-POISE-2-acc14PeriOperative ISchemic Evaluation-2 Trial (POISE-2)
P.J. Devereaux | Population Health Research Institute, Hamilton, Canada
Presentation Slides (PDF) | Summary Slide (PDF)

Related Science:
image-clonidine-acc14A Large International Trial Assessing the Effects of Clonidine on Major Arterial Events in Patients Having Noncardiac Surgery
Daniel I. Sessler | Outcomes Research, Cleveland Clinic, Cleveland, OH
Presentation Slides (PDF) | Summary Slide (PDF)

Related Science:
image-SIRS-acc14Steroids In caRdiac Surgery Trial (SIRS Trial)
Richard Whitlock | Population Health Research Institute, McMaster University/Hamilton Health Sciences, Hamilton, Canada
Summary Slide (PDF)

Related Science:
image-GIPS-III-acc14Metformin in Acute Myocardial Infarction (GIPS-III)
Chris PH Lexis | Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Summary Slide (PDF)

Related Science:
image-STAMPEDE-acc14Effect of Bariatric Surgery vs. Intensive Medical Therapy on Long-term Glycemic Control and Complications of Diabetes: 3-Year STAMPEDE Trial Results
Philip Raymond Schauer | Cleveland Clinic, Cleveland, OH
Summary Slide (PDF)

Related Science:

Session: 405 Late-Breaking Clinical Trials V: TCT@ACC-i2
image-TVT-Registry-acc14One Year Outcomes from the STS/ACC Transcatheter Valve Therapy (TVT) Registry
David R. Holmes | Mayo Clinic, Rochester, MN
Summary Slide (PDF)

Related Science:
image-NEXT-acc14Two-year Outcome of a Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer: The NEXT trial
Masahiro Natsuaki | Saiseikai Fukuoka General Hospital, Fukuoka, Japan
Presentation slides (PDF) | Summary Slide (PDF)

Related Science:
image-HEAT-PPCI-acc14How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention (HEAT-PPCI)
Abdel Shahzad | Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital NHS Trust, Liverpool, United Kingdom
Summary Slide (PDF)

Related Science:
image-ZEUS-acc14Bare Metal vs. Zotarolimus-eluting stent in Uncertain Drug-eluting Stent Candidates: A Randomized Controlled Trial (ZEUS)
Marco Valgimigli | Erasmus MC, Rotterdam, The Netherlands
Presentation Slides (PDF) | Summary Slide (PDF)

Related Science:
image-MSC-HF-acc14Autotransplantation of Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Severe Ischemic Heart Failure: The MSC-HF Trial
Anders Bruun Mathiasen | Copenhagen University Hospital, Copenhagen, Denmark
Presentation Slides (PDF) | Summary Slide (PDF)

Related Science:

Connect with AHA Science News

Follow AHAScience on Twitter (opens in new window)
Like AHA Science News on Facebook (opens in new window)

Professional Online Network

Connect with over 30,000 heart and stroke professionals.

Become A Member

Become a professional member of the American Heart Association/American Stroke Association.

Join or renew your AHA/ASA Professional Membership
to qualify for members-only awards, and:

• Affiliate with one of 16 Scientific Councils.
• Save on AHA/ASA Scientific Sessions.
• Save on print publications.
• Apply for research funding and not pay a fee
• Enjoy many more membership benefits.

Promo code: WDJ008ZZ

AHA Science News on YouTube

Subscribe to AHA's Science News Channel (opens in new window) on YouTube for exclusive, late-breaking coverage of over 200 video interviews, panel discussions, welcome messages and more.